Status:
COMPLETED
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Lead Sponsor:
University of California, Irvine
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Urinary Incontinence
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Prostate cancer is the most common non-cutaneous malignancy in men and is the 2nd leading cause of death from cancer in men. Radical prostatectomy is one of the treatment options available for organ-c...
Eligibility Criteria
Inclusion
- Patients that have been diagnosed with prostate cancer and will undergo treatment for the disease as part of standard clinical care
- Patients that have multiple pad use a few days after standard of care catheter removal
Exclusion
- Contra-indication to Solifenacin
- Narrow angle glaucoma
- Hepatic impairment
- Renal impairment
- CYP3A4 inhibitors (e.g. Ketoconazole)
- Gastric Retention (delayed or slow emptying of the stomach)
- Lives in a different country
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01215721
Start Date
October 1 2010
End Date
May 1 2013
Last Update
January 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Irvine Medical Center
Orange, California, United States, 92868